Types segmentation classifies topical retinoids by active pharmaceutical ingredient, each exhibiting distinct potency, safety profile, and market positioning. Tretinoin (all‑trans retinoic acid) remains the highest‑strength prescription molecule, representing roughly 30 % of the market due to its extensive dermatologic indications and established supply chain. Adapalene, a third‑generation synthetic retinoid, accounts for about 25 % of sales, benefiting from a favorable safety margin that enables over‑the‑counter availability in many regions. Tazarotene, another prescription‑only retinoic acid derivative, captures approximately 15 % of revenue, driven by its efficacy in psoriasis and severe acne. Retinol and its ester retinyl palmitate, classified as over‑the‑counter cosmeceuticals, together contribute near 20 % of the market, reflecting consumer demand for milder anti‑aging agents. Retinaldehyde occupies the remaining 10 %, positioned as an intermediate‑potency option that bridges prescription and cosmetic segments. This market taxonomy illustrates how potency gradients and regulatory status shape the revenue distribution across retinoid types, with prescription‑grade agents dominating clinical applications and milder derivatives fueling the OTC segment.
